Aptatek BioSciences appoints Lee McCracken to its Board as Non-Executive Director

– USA, NJ –  Aptatek BioSciences, Inc., a developer of pioneering home monitoring tools for chronic disease patients, today announced the appointment of Lee McCracken to its Board as a Non-Executive Director.

“Aptatek’s advanced technology has the potential to tap into a multi-billion-dollar market for at-home monitoring devices. Lee has deep knowledge of the space and practical experience in the commercialization of new technology, which we will call on to help us deliver the full potential of our technology.” said Board Chair, Dr. Jason Smith.

About Lee McCracken

Lee McCracken has more than 30 years of pharmaceutical, biotech, diagnostics, device, and venture capital experience. He has held leadership and P&L roles in private and public companies, from startups to the commercial stage.

Lee McCracken is Chairperson of Drawbridge Health, where he was previously recruited as CEO by GE Ventures and GE Healthcare. His extensive experience in corporate development, strategic partnering, fundraising, and M&A from Allergan to Prometheus Laboratories will be invaluable as Aptatek continues to develop home monitoring solutions that empower patients to take control of their health.

“I’m impressed with the technology being developed at Aptatek and their passion for providing individuals with chronic diseases the tools necessary to live healthier and more fulfilling lives,” said Lee McCracken. “I believe that collectively, we can revolutionize how chronic diseases are managed and improve patient outcomes worldwide.”

About Aptatek BioSciences, Inc.

Aptatek BioSciences, Inc. is a spinout of Columbia University at the forefront of developing home monitoring tools for chronic disease patients utilizing novel aptamer chemistry. With a mission to empower individuals with chronic diseases to manage their health more effectively, Aptatek BioSciences, Inc. combines cutting-edge aptamer technology, data-driven insights, and a patient-centric approach to revolutionize healthcare management. Aptatek hopes to revolutionize Phenylketonuria monitoring and expand to other chronic disease states.

SOURCE: https://aptatek.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.